^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYCL amplification

    i
    Other names: MYCL, MYCL Proto-Oncogene BHLH Transcription Factor, Class E Basic Helix-Loop-Helix Protein 38, Myc-Related Gene From Lung Cancer, Protein L-Myc-1, Protein L-Myc, BHLHe38 , MYCL1, LMYC, V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 1 Lung Carcinoma Derived 2, V-Myc Avian Myelocytomatosis Viral Oncogene Lung Carcinoma Derived Homolog 3, V-Myc Myelocytomatosis Viral Oncogene Homolog 1 Lung Carcinoma Derived 3, V-Myc Myelocytomatosis Viral Oncogene Homolog, L-Myc-1 Proto-Oncogene, L-Myc Prote
    Entrez ID:
    4610
    Related biomarkers:
    Expression
    11ms
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=156, Active, not recruiting, AstraZeneca | Phase classification: P1b --> P1 | Trial completion date: Sep 2023 --> Jun 2024
    Phase classification • Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD8 (cluster of differentiation 8) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    over1year
    Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients (IASLC-WCLC 2023)
    Though subset analysis of randomized clinical trials did not show a predictive benefit of high TMB in patients who received chemoimmunotherapy in SCLC, we found that high TMB may be a prognostic factor in SCLC patients receiving chemotherapy +/- PD-L1 ICI. Although our study did not find GA associated with exceptionally favorable TTNT, further studies focused on specific alterations are needed to investigate additional genomic markers of chemoimmunotherapy effectiveness in SCLC, including RNA expression analysis.
    Clinical • Real-world evidence • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    TP53 mutation • TMB-H • PTEN mutation • KMT2D mutation • MLL2 mutation • MLL mutation • MYCL amplification
    over1year
    Mutational-Copy Number Variation Profile and Immunotherapy Drivers in Neuroendocrine Lung Carcinomas: PD-L1, Microsatellite Instability, DNA Mismatch Repair Genes Expression and Tumor Mutational Burden in a Series of 30 Cases (AMP Europe 2023)
    In this series of lung neuroendocrine carcinomas, TP53 and RB1 mutations were the most prevalent. No tumors showed H-MSI or dMMR. Only 3 expressed PD-L1.
    Clinical • Mismatch repair • Tumor mutational burden • Microsatellite instability • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NOTCH1 (Notch 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • NKX2-1 (NK2 Homeobox 1) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • SYP (Synaptophysin) • HNF1A (HNF1 Homeobox A)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • PTEN mutation • ARID1A mutation • STK11 mutation • RB1 mutation • MYCL amplification • RB1 mutation + TP53 mutation
    |
    Oncomine Tumor Mutation Load Assay
    over1year
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1b, N=156, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2023 --> Sep 2023
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    over1year
    Comprehensive clinical and genomic analysis for patients with MYC, MYCN, and MYCL amplified solid tumors (AACR 2023)
    While MYCf amplification is observed across a broad range of cancer types, factors such as gene type (MYC, MYCN, MYCL), focality, total copy number, clonality, and concurrent oncogenic drivers vary widely. Novel MYC-directed trials may consider enrichment for a subpopulation of cancers with higher-level, focal, and clonal MYCf amplifications without concurrent other drivers.
    Clinical • Omic analysis
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYCL amplification
    |
    MSK-IMPACT
    2years
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1b, N=156, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2022 --> Mar 2023
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    over2years
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1b, N=156, Active, not recruiting, AstraZeneca | Trial completion date: Feb 2022 --> Sep 2022
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    3years
    Carcinoma with Triphasic Differentiation Arising from Inverted Papilloma in Sinonasal Sinus: A Rare Case with Molecular Characterization. (PubMed, Diagnostics (Basel))
    Oncogenic mutations such as FBXW7, TP53, and EGFR were detected in both SNEC and sarcomatoid carcinoma, and MYCL amplification was observed only in the SNEC component. This case highlights an extremely rare presentation of combined SNEC and sarcomatoid carcinoma arising from an inverted papilloma in the sinonasal sinus.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    TP53 mutation • EGFR mutation • MYCL amplification
    over3years
    MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma. (PubMed, Pathol Oncol Res)
    3/46 (6.5%) was positive for L-myc protein expression, and 4/46 (8.7%) was positive for c-Myc protein expression. Our study firstly multidimensional explored the expression of MYCL1 amplification, L-Myc and c-Myc protein and investigated clinicopathological characteristics and survival status in patients with surgically resected SCLC, which makes a contribution to subsequent research and therapeutic strategies.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    MYC expression • MYCL amplification